thrombotic$83272$ - translation to ελληνικό
Display virtual keyboard interface

thrombotic$83272$ - translation to ελληνικό

HUMAN DISEASE
Shulman-Upshaw syndrome; Moschcowitz disease; Upshaw-Shulman syndrome; Familial Thrombotic Thrombocytopenia Purpura; Moschkowitz Disease; Purpura, Thrombotic Thrombocytopenic; Thrombotic microangiopathy, familial; Purpura, thrombotic thrombocytopenic; Thrombotic thrombocytopaenic purpura; Upshaw-Schülman syndrome; Moschcowitz syndrome; Upshaw–Schülman syndrome; TTP (disease); TTP (disorder)

thrombotic      
adj. θρομβωτικός

Ορισμός

thromboembolism
[??r?mb??'?mb?l?z(?)m]
¦ noun Medicine obstruction of a blood vessel by a blood clot that has become dislodged from its original site.
Derivatives
thromboembolic adjective

Βικιπαίδεια

Thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body. This results in a low platelet count, low red blood cells due to their breakdown, and often kidney, heart, and brain dysfunction. Symptoms may include large bruises, fever, weakness, shortness of breath, confusion, and headache. Repeated episodes may occur.

In about half of cases a trigger is identified, while in the remainder the cause remains unknown. Known triggers include bacterial infections, certain medications, autoimmune diseases such as lupus, and pregnancy. The underlying mechanism typically involves antibodies inhibiting the enzyme ADAMTS13. This results in decreased break down of large multimers of von Willebrand factor (vWF) into smaller units. Less commonly TTP is inherited, known as Upshaw–Schulman syndrome, such that ADAMTS13 dysfunction is present from birth. Diagnosis is typically based on symptoms and blood tests. It may be supported by measuring activity of or antibodies against ADAMTS13.

With plasma exchange the risk of death has decreased from more than 90% to less than 20%. Immunosuppressants, such as glucocorticoids, and rituximab may also be used. Platelet transfusions are generally not recommended.

About 1 per 100,000 people are affected. Onset is typically in adulthood and women are more often affected. About 10% of cases begin in childhood. The condition was first described by Eli Moschcowitz in 1924. The underlying mechanism was determined in the 1980s and 1990s.